| Literature DB >> 35747791 |
Gloria Ravegnini1, Francesca Gorini1, Giulia Dondi2,3, Marco Tesei2, Eugenia De Crescenzo2,3, Alessio G Morganti4, Patrizia Hrelia1, Pierandrea De Iaco2,3, Sabrina Angelini1, Anna Myriam Perrone2,3.
Abstract
Cervical cancer is a common female cancer, with nearly 600,000 cases and more than 300,000 deaths worldwide every year. From a clinical point of view, surgery plays a key role in early cancer management, whereas advanced stages are treated with chemotherapy and/or radiation as adjuvant therapies. Nevertheless, predicting the degree of cancer response to chemotherapy or radiation therapy at diagnosis in order to personalize the clinical approach represents the biggest challenge in locally advanced cancers. The feasibility of such predictive models has been repeatedly assessed using histopathological factors, imaging and nuclear methods, tissue and fluid scans, however with poor results. In this context, the identification of novel potential biomarkers remains an unmet clinical need, and microRNAs (miRNAs) represent an interesting opportunity. With this in mind, the aim of this systematic review was to map the current literature on tumor and circulating miRNAs identified as significantly associated with the therapeutic response in cervical cancer; finally, a perspective point of view sheds light on the challenges ahead in this tumor. Systematic Review Registration: PROSPERO (CRD42021277980).Entities:
Keywords: HPV; cervical cancer; chemotherapy; miRNAs; radiotherapy; therapeutic response
Year: 2022 PMID: 35747791 PMCID: PMC9209727 DOI: 10.3389/fonc.2022.847974
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 5.738